Core Viewpoint - The company, Watson Pharmaceuticals, has received approval from the Chongqing Drug Administration for the re-registration of three pharmaceutical products, indicating a positive regulatory development for the company [1] Group 1: Product Approvals - The approved products include Oyster Calcium Carbonate Granules, Cefalexin Capsules, and Lincomycin Hydrochloride Capsules [1] - The approval for Oyster Calcium Carbonate Granules is valid until May 9, 2030 [1] - The approval for Cefalexin Capsules is valid until April 28, 2030 [1] - The approval for Lincomycin Hydrochloride Capsules is valid until May 9, 2030 [1]